Andrew Singer
Director/Board Member at ENLIVEX THERAPEUTICS LTD.
Profile
Mr. Andrew E.
Singer is an Independent Director at Enlivex Therapeutics Ltd.
He is on the Board of Directors at Enlivex Therapeutics Ltd.
and J.F.
Kapnek Trust.
Mr. Singer was previously employed as a CFO, Treasurer & EVP-Finance & Administration by Epizyme, Inc., a Head-Health Care Investment Banking Group by RBC Capital Markets Corp., and a Co-Founder by MVC Capital, Inc. He received his undergraduate degree from Yale University and an MBA from Harvard Business School.
Andrew Singer active positions
Companies | Position | Start |
---|---|---|
ENLIVEX THERAPEUTICS LTD. | Director/Board Member | 2023-04-16 |
J.F. Kapnek Trust | Director/Board Member | - |
Former positions of Andrew Singer
Companies | Position | End |
---|---|---|
EPIZYME, INC. | Director of Finance/CFO | 2017-08-30 |
RBC Capital Markets Corp. | Corporate Officer/Principal | 2014-12-31 |
MVC CAPITAL, INC. | Founder | - |
Training of Andrew Singer
Yale University | Undergraduate Degree |
Harvard Business School | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ENLIVEX THERAPEUTICS LTD. | Health Technology |
Private companies | 4 |
---|---|
MVC Capital, Inc.
MVC Capital, Inc. Investment ManagersFinance MVC Capital, Inc is private Equity fund invest in equity and debt investment capital to fund growth, acquisitions, and recapitalizations of small and middle-market companies located in the United States. company operates through the MVC and MVCFS segments. The MVC segment consists of MVC Cayman and MVC Turf. The MVCFS segment refers to its subsidiary which provides advisory, administrative, and other services to the company and its portfolio companies. It participates in senior and subordinated loans, common and preferred stock, and warrants or rights to acquire equity interests, or convertible securities requirements. | Finance |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
RBC Capital Markets Corp. | Finance |
J.F. Kapnek Trust |
- Stock Market
- Insiders
- Andrew Singer